Established in January 2006, Sonke Pharmaceuticals (Pty) is a Black Economic Empowerment joint venture between Ranbaxy (Pty) Ltd and Community Investment Holdings.
Sonke Pharmaceuticals has so far opened 21 products to date, nine of which are manufactured locally in South Africa. The organisation is committed to acting responsibly in all economic, social and environmental aspects of its business.
Sonke Pharmaceuticals highly regards its clients that have enabled its success. The organisation places a first-class personal well being of its directors, management and support staff. Sonke Pharmaceuticals has created and endlessly strived to uphold a professional and creative working environment where personnel feel welcome and appreciated for their efforts and contribution. The company is level 5 B-BBEE Empowerdex BEE Contributor-Rating with majority staff qualifying as historically disadvantaged individuals confirms its commitment to transformation and empowerment.
Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited is India’s largest pharmaceutical company, it is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies,” resulting in a number of products under development. Sonke Pharmaceuticals is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.